Polydimethylsiloxane Releasing Matrix Metalloprotease Inhibitors, as Model Intraocular Lens Materials, for Mitigating Posterior Capsule Opacification

Abstract

<p>Improved materials for implantation as intraocular lens (IOL) devices are needed to minimize the occurrence of posterior capsule opacification (PCO). In this work, novel polydimethylsiloxane (PDMS) loaded with matrix metalloprotease inhibitors (MMPI) were developed as model IOL materials.</p> <p>PDMS was chosen as silicones are currently used successfully as IOLs. Inhibitor release rates and amount of initial burst of drug-loaded PDMS could be controlled by changing solvent when loading into elastomer base, as well as drug loading method, and release buffer.</p> <p>Two lens epithelial cell lines were characterized for in vitro tests: FHL124 and HLE B3. These cell lines produce different combinations of extracellular matrix proteins when grown on various biomaterial surfaces. Significant differences between the two cell lines were observed both in collagen VIII and α-smooth muscle actin levels, both when cells were unstimulated, and as a result of epithelial to mesenchymal transition induced by treatment with transforming growth factor β2. FHL124 cells were selected in further tests due to their consistent expression of extracellular matrix components when exposed to different materials.</p> <p>Solutions of synthetic MMPI GM6001 and MMP 2/9 Inhibitor II, known to mitigate anterior subcataract formation, were released from PDMS and found to protect in a modest but significant way against protein profile changes and to delay migration. Due to the Zn²⁺ dependence of MMPs, chelators, including EDTA, TPEN and 1-10 phenanthroline were examined as alternative inhibitors. Only the latter was found to have a significant effect on cell migration rates in vitro. Sulfadiazine, due to its chemical resemblance to synthetic MMPI was determined to be the most efficient at reducing migration rates as well as to have the lowest toxicity.</p> <p>Overall, sulfadiazine was determined in this work to be a potentially effective solution to mitigating PCO. These results indicate that releasing MMPI molecules from PDMS as a model IOL is a promising way to mitigate aspects of PCO.</p>